(1541946) Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Primary Author; Presenting Author(s)

• 

  Florian Simon, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany

Co-Author(s)

• RL

  Rudy Ligtvoet, PhD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• SR

  Sandra Robrecht, PhD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• 

  Paula Cramer, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• NK

  Nadine Kutsch, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• 

  Moritz Fürstenau, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• VG

  Valentin Goede, MD

  Department of Oncogeriatrics, St. Marien-Hospital
  Cologne, Germany
• Jv

  Julia von Tresckow, MD

  Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne and Duesseldorf, German CLL Study Group, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen
  Essen, Germany
• 

  Petra Langerbeins, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• AF

  Anna Fink, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• HH

  Henriette Huber, MD

  Städtisches Klinikum Karlsruhe
  Karlsruhe, Germany
• 

  Eugen Tausch, MD

  Treating physician and research fellow
  Department of Internal Medicine III, Ulm University
  Ulm, Germany
• CS

  Christof Schneider, MD

  MD
  Department of Internal Medicine III, Ulm University
  Ulm, Germany
• CW

  Clemens M. Wendtner, MD

  Head physician
  Department of Hematology, Oncology, Immunology, Palliative Care, Munich Clinic Schwabing
  Munich, Germany
• MR

  Matthias Ritgen, MD

  Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Germany
• MD

  Martin Dreyling, MD

  Klinikum der Universität München, Ludwig Maximilian University of Munich
  Munich, Germany
• LM

  Lothar Müller, MD

  Study Centrum Unter Ems, Practice for Oncology and Hematology
  Leer, Germany
• LJ

  Lutz Jacobasch, MD

  Praxis of Haematology and Oncology
  Dresden, Germany
• WH

  Werner Heinz, MD

  Medical Clinic II, Caritas Hospital Bad Mergentheim, Uhlandstr, 7D-97980
  Bad Mergentheim, Germany
• UV

  Ursula Vehling-Kaiser, MD

  Praxis für Hämatologie/Onkologie
  Landshut, Germany
• LS

  Lilly Sivcheva, MD

  First Internal Department, MHAT Hristo Botev, AD
  Vratsa, Bulgaria
• SB

  Sebastian Böttcher, MD

  Clinic for Internal Medicine III (Hematology, Oncology, Palliative Care), Rostock University Medical School
  Rostock, Germany
• 

  Peter Dreger, MD

  CLL Program Leader
  Department V of Internal Medicine, University Hospital Heidelberg
  Heidelberg University Hospital
  Heidelberg, Germany
• TI

  Thomas Illmer, MD

  Group Practice for Hematology and Oncology
  Dresden, Germany
• MG

  Michael Gregor, MD

  Senior consultant
  Department of Hematology, Luzerner Kantonsspital
  Luzern, Switzerland
• PS

  Philipp Staber, MD

  Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna
  Vienna, Austria
• 

  Stephan Stilgenbauer, MD, PhD

  Department of Internal Medicine III, Ulm University
  Ulm, Germany
• 

  Carsten Utoft Niemann, MD, PhD

  Associate Professor, Chief Physician
  Department of Hematology, Copenhagen University Hospital Rigshospitalet, Denmark; Hematology Research Group, Danish Cancer Institute Research Center, Denmark; Department of Clinical Medicine, Copenhagen University
  Copenhagen, Denmark
• 

  Arnon P. Kater, MD, PhD

  Deputy Head, Clinical Hematologist, Head of Research Lab
  Department of Hematology, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam
  Amsterdam, Netherlands
• 

  Kirsten Fischer, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne
  Cologne, Germany
• 

  Barbara Eichhorst, MD

  Associate Professor, Consultant Hematologist
  University Hospital of Cologne
  Cologne, Germany
• 

  Michael Hallek, MD

  Faculty of Medicine and University Hospital Cologne
  Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne
  Cologne, Germany
• 

  Othman Al-Sawaf, MD

  Faculty of Medicine
  University Hospital Cologne
  Cologne, Germany